93 related articles for article (PubMed ID: 23645730)
1. Identification of HLA class I-binding peptides derived from unique cancer-associated proteins by mass spectrometric analysis.
Kamata Y; Kuhara A; Iwamoto T; Hayashi K; Koido S; Kimura T; Egawa S; Homma S
Anticancer Res; 2013 May; 33(5):1853-9. PubMed ID: 23645730
[TBL] [Abstract][Full Text] [Related]
2. A novel tumor-associated antigen, cell division cycle 45-like can induce cytotoxic T-lymphocytes reactive to tumor cells.
Tomita Y; Imai K; Senju S; Irie A; Inoue M; Hayashida Y; Shiraishi K; Mori T; Daigo Y; Tsunoda T; Ito T; Nomori H; Nakamura Y; Kohrogi H; Nishimura Y
Cancer Sci; 2011 Apr; 102(4):697-705. PubMed ID: 21231984
[TBL] [Abstract][Full Text] [Related]
3. Cyclin-dependent kinaselike 5 is a novel target of immunotherapy in adult T-cell leukemia.
Kawahara M; Hori T; Matsubara Y; Okawa K; Uchiyama T
J Immunother; 2007; 30(5):499-505. PubMed ID: 17589290
[TBL] [Abstract][Full Text] [Related]
4. Proteomic identification of an MHC-binding peptidome from pancreas and breast cancer cell lines.
Antwi K; Hanavan PD; Myers CE; Ruiz YW; Thompson EJ; Lake DF
Mol Immunol; 2009 Sep; 46(15):2931-7. PubMed ID: 19615748
[TBL] [Abstract][Full Text] [Related]
5. Identification of squamous cell carcinoma antigen-derived peptides having the capacity of inducing cancer-reactive CTLs in HLA-A24+ cancer patients.
Homma S; Harada M; Yano H; Ogasawara S; Shichijo S; Matsueda S; Komatsu N; Shomura H; Maeda Y; Sato Y; Todo S; Itoh K
Int J Oncol; 2006 Sep; 29(3):577-87. PubMed ID: 16865273
[TBL] [Abstract][Full Text] [Related]
6. Peptides derived from the whole sequence of BCR-ABL bind to several class I molecules allowing specific induction of human cytotoxic T lymphocytes.
Buzyn A; Ostankovitch M; Zerbib A; Kemula M; Connan F; Varet B; Guillet JG; Choppin J
Eur J Immunol; 1997 Aug; 27(8):2066-72. PubMed ID: 9295046
[TBL] [Abstract][Full Text] [Related]
7. Prostate stem cell antigen is a promising candidate for immunotherapy of advanced prostate cancer.
Dannull J; Diener PA; Prikler L; Fürstenberger G; Cerny T; Schmid U; Ackermann DK; Groettrup M
Cancer Res; 2000 Oct; 60(19):5522-8. PubMed ID: 11034097
[TBL] [Abstract][Full Text] [Related]
8. Immunodominance across HLA polymorphism: implications for cancer immunotherapy.
Kim CJ; Parkinson DR; Marincola F
J Immunother; 1998 Jan; 21(1):1-16. PubMed ID: 9456431
[TBL] [Abstract][Full Text] [Related]
9. Class I-restricted alloreactive cytotoxic T lymphocytes recognize a complex array of specific MHC-associated peptides.
Wang W; Man S; Gulden PH; Hunt DF; Engelhard VH
J Immunol; 1998 Feb; 160(3):1091-7. PubMed ID: 9570521
[TBL] [Abstract][Full Text] [Related]
10. Isolation of novel HLA-DR restricted potential tumor-associated antigens from the melanoma cell line FM3.
Halder T; Pawelec G; Kirkin AF; Zeuthen J; Meyer HE; Kun L; Kalbacher H
Cancer Res; 1997 Aug; 57(15):3238-44. PubMed ID: 9242455
[TBL] [Abstract][Full Text] [Related]
11. Purification and HPLC-MS analysis of a naturally processed HCMV-derived peptide isolated from the HEK-293T/HLA-E+/Ul40+ cell transfectants and presented at the cell surface in the context of HLA-E.
Millo E; Pietra G; Armirotti A; Vacca P; Mingari MC; Moretta L; Damonte G
J Immunol Methods; 2007 Apr; 322(1-2):128-36. PubMed ID: 17331531
[TBL] [Abstract][Full Text] [Related]
12. Direct identification of human tumor-associated peptide antigens and a preclinical model to evaluate their use.
Engelhard VH; Bullock TN; Colella TA; Mullins DW
Cancer J; 2000 May; 6 Suppl 3():S272-80. PubMed ID: 10874498
[TBL] [Abstract][Full Text] [Related]
13. Two proliferation-related proteins, TYMS and PGK1, could be new cytotoxic T lymphocyte-directed tumor-associated antigens of HLA-A2+ colon cancer.
Shichijo S; Azuma K; Komatsu N; Ito M; Maeda Y; Ishihara Y; Itoh K
Clin Cancer Res; 2004 Sep; 10(17):5828-36. PubMed ID: 15355913
[TBL] [Abstract][Full Text] [Related]
14. Mapping of HLA class I binding motifs in forty-four fusion proteins involved in human cancers.
Gambacorti-Passerini C; Bertazzoli C; Dermime S; Scardino A; Schendel D; Parmiani G
Clin Cancer Res; 1997 May; 3(5):675-83. PubMed ID: 9815736
[TBL] [Abstract][Full Text] [Related]
15. An in vitro-transcribed-mRNA polyepitope construct encoding 32 distinct HLA class I-restricted epitopes from CMV, EBV, and Influenza for use as a functional control in human immune monitoring studies.
Nielsen JS; Wick DA; Tran E; Nelson BH; Webb JR
J Immunol Methods; 2010 Aug; 360(1-2):149-56. PubMed ID: 20637775
[TBL] [Abstract][Full Text] [Related]
16. Binding of BCR/ABL junctional peptides to major histocompatibility complex (MHC) class I molecules: studies in antigen-processing defective cell lines.
Cullis JO; Barrett AJ; Goldman JM; Lechler RI
Leukemia; 1994 Jan; 8(1):165-70. PubMed ID: 8289483
[TBL] [Abstract][Full Text] [Related]
17. The TAG family of cancer/testis antigens is widely expressed in a variety of malignancies and gives rise to HLA-A2-restricted epitopes.
Adair SJ; Carr TM; Fink MJ; Slingluff CL; Hogan KT
J Immunother; 2008 Jan; 31(1):7-17. PubMed ID: 18157007
[TBL] [Abstract][Full Text] [Related]
18. Expression of a newly defined tumor-rejection antigen SART3 in musculoskeletal tumors and induction of HLA class I-restricted cytotoxic T lymphocytes by SART3-derived peptides.
Tsuda N; Murayama K; Ishida H; Matsunaga K; Komiya S; Itoh K; Yamada A
J Orthop Res; 2001 May; 19(3):346-51. PubMed ID: 11398844
[TBL] [Abstract][Full Text] [Related]
19. Immunization of patients with melanoma peptide vaccines: immunologic assessment using the ELISPOT assay.
Pass HA; Schwarz SL; Wunderlich JR; Rosenberg SA
Cancer J Sci Am; 1998; 4(5):316-23. PubMed ID: 9815296
[TBL] [Abstract][Full Text] [Related]
20. Large scale mass spectrometric profiling of peptides eluted from HLA molecules reveals N-terminal-extended peptide motifs.
Escobar H; Crockett DK; Reyes-Vargas E; Baena A; Rockwood AL; Jensen PE; Delgado JC
J Immunol; 2008 Oct; 181(7):4874-82. PubMed ID: 18802091
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
